Last reviewed · How we verify
Hydralazine Isosorbide Dinitrate
Hydralazine Isosorbide Dinitrate, marketed by Henrik Wiggers, is a combination therapy currently available in the cardiovascular market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Hydralazine Isosorbide Dinitrate |
|---|---|
| Also known as | BiDil |
| Sponsor | Henrik Wiggers |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Baroreflex Activation Therapy for Heart Failure (NA)
- DANHEART (H-HeFT and Met-HeFT) (PHASE4)
- Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension (NA)
- Hypertensive Heart Failure Treatment in SSA (PHASE4)
- Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts (PHASE4)
- Genomic Response Analysis of Heart Failure Therapy in African Americans
- Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction (PHASE2)
- Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |